Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases

被引：30

作者：

Seyedmousavi, Seyedmojtaba ^{[1
,2
]}

Verweij, Paul E. ^{[2
]}

Mouton, Johan W. ^{[1
,2
]}

机构：

[1] Erasmus MC, Dept Med Microbiol & Infect Dis, NL-3000 CA Rotterdam, Netherlands

[2] Radboudumc, Dept Med Microbiol, Nijmegen, Netherlands

来源：

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | 2015年 / 13卷 / 01期

关键词：

isavuconazole; pharmacodynamics; pharmacokinetics; systemic fungal infections; IN-VITRO ACTIVITY; PHARMACODYNAMIC TARGET DETERMINATION; WATER-SOLUBLE PRODRUG; 8 ANTIFUNGAL DRUGS; CRYPTOCOCCUS-GATTII; ASPERGILLUS-FUMIGATUS; DOSE PHARMACOKINETICS; FUNGICIDAL ACTIVITIES; EUROPEAN COMMITTEE; AZOLE ANTIFUNGALS;

D O I：

10.1586/14787210.2015.990382

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The prodrug isavuconazonium sulfate (BAL8557) is an extended-spectrum water-soluble triazole, developed for the treatment of severe invasive and life-threatening fungal diseases. Its active moiety, BAL4815, is a potent inhibitor of ergosterol biosynthesis, resulting in the disruption of fungal membrane structure and function. The active compound shows broad-spectrum of activity and potency against all major opportunistic fungi, such as Aspergillus spp., Candida spp., Cryptococcus spp., Mucorales, Black yeasts and their filamentous relatives and the true pathogenic fungi, including Histoplasma capsulatum and Blastomyces dermatitidis. It is currently in Phase III clinical development for treatment of aspergillosis, candidiasis and mucormycosis, as well as other rare fungi infections. We reviewed the pharmacokinetic and pharmacodynamic characteristics of isavuconazole, and its microbiological and clinical investigation progress in advanced stages of development.

引用

页码：9 / 27

页数：19

共 117 条

[1] EUCAST Testing of Isavuconazole Susceptibility in Aspergillus: Comparison of Results for Inoculum Standardization Using Conidium Counting versus Optical Density [J].

Arendrup, Maiken Cavling ;

Howard, Susan ;

Lass-Floerl, Cornelia ;

Mouton, Johan W. ;

Meletiadis, Joseph ;

Cuenca-Estrella, Manuel .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (11) :6432-6436

[2]

Astellas Pharma, 2013, CLIN INFECT DIS, V57, pIi

[3] Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study [J].

Auberger, Jutta ;

Lass-Floerl, Cornelia ;

Aigner, Maria ;

Clausen, Johannes ;

Gastl, Guenther ;

Nachbaur, David .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (09) :2268-2273

[4]

Badali H, 2009, MYCOSES, V52, P102

[5] Invasive mold infections in allogeneic bone marrow transplant recipients [J].

Baddley, JW ;

Stroud, TP ;

Salzman, D ;

Pappas, PG .

CLINICAL INFECTIOUS DISEASES, 2001, 32 (09) :1319-1324

[6] New azole antifungals.: 3.: Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones [J].

Bartroli, J ;

Turmo, E ;

Algueró, M ;

Boncompte, E ;

Vericat, ML ;

Conte, L ;

Ramis, J ;

Merlos, M ;

García-Rafanell, J ;

Forn, J .

JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (11) :1869-1882

[7]

Bartroli X, 2005, 45 INT C ANT AG CHEM

[8]

Basilea Pharma, 2014, BAS REP IS REC QIDP

[9]

Basilea Pharmaceutica, 2014, BAS SUBM IS EUR MARK

[10] Iatrogenic Exserohilum infection of the central nervous system: mycological identification and histopathological findings [J].

Bell, W. Robert ;

Dalton, Justin B. ;

McCall, Chad M. ;

Karram, Sarah ;

Pearce, David T. ;

Memon, Warda ;

Lee, Richard ;

Carroll, Karen C. ;

Lyons, Jennifer L. ;

Gireesh, Elakkat D. ;

Trivedi, Julie B. ;

Cettomai, Deanna ;

Smith, Bryan R. ;

Chang, Tiffany ;

Tochen, Laura ;

Ratchford, John N. ;

Harrison, Daniel M. ;

Ostrow, Lyle W. ;

Stevens, Robert D. ;

Chen, Li ;

Zhang, Sean X. .

MODERN PATHOLOGY, 2013, 26 (02) :166-170

← 1 2 3 4 5 6 7 8 9 10 →